Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference

WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that President and Chief Executive Officer, Steve Mahoney, will discuss the company’s progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California….
Click here to view original post

Advertisement — Advertise with Biotech Networks